Cyclo Therapeutics Profit Margin

Cyclo Therapeutics (CYTH) currently reports a profit margin of -2848.16% as of September 2024. That compares with -2019.93% in the prior-year period — down 41.0% year over year. That is below the Healthcare sector average of 9.48%. Use the charts on this page to explore Cyclo Therapeutics's profit margin history and peer comparisons.

Cyclo Therapeutics's profit margin decreased from -2019.93% to -2848.16% — a 41.0% year-over-year decrease (period ending September 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Cyclo Therapeutics's profit margin of -2848.16% is lower than the Healthcare sector average of 9.48%. That is roughly 30140.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Cyclo Therapeutics's current -2848.16% should be judged against Healthcare norms (sector average: 9.48%) and against CYTH's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -2848.16%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 9.48%. From there, open related valuation or income-statement pages for Cyclo Therapeutics, and consider following CYTH for alerts when major investors trade the stock.